contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


qlife-holding-ab-qlife-has-signed-a-letter-of-intent-with-a-top-20-global-pharma-company-to-explore-a-potential-commercial-collaboration-1

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Qlife Holding AB is a med-tech group that strives to revolutionize the market for clinical biomarkers and virus tests. By enabling tests at home as a complement to tests in healthcare, access to important health information is facilitated, which can contribute to better treatment and potentially prevent diseases. The first capsules in the company's product, Egoo.Health Platform, were CE-marked for professional use in early 2020. The company has patent protection for key parts of its technology. The Danish-based company is listed on Nasdaq First North Stockholm.

Husk at læse hele vores research disclaimer på https://www.inderes.dk/disclaimer. Qlife Holding AB er en medicinsk teknologi virksomhed, der stræber efter at revolutionere markedet for kliniske biomarkører- og virustest. Ved at muliggøre test/diagnostik i hjemmet som et supplement til test i sundhedsvæsenet, lettes adgangen til vigtig helbredsinformation, som kan bidrage til bedre behandling og potentielt forebygge sygdomme. Qlife Holding blev dannet i oktober 2019 og modtog samme år certificeringen ISO 13485:2016, hvilket betyder, at Qlife opfylder alle krav til fremstilling og salg af in vitro diagnostiske analysatorer og reagenser. De første kapsler i virksomhedens produkt, Egoo.Health Platform, blev CE-mærket til professionel brug i begyndelsen af ​​2020. Virksomheden har patentbeskyttelse på centrale dele af sin teknologi.

Qlife Holding

Qlife has been in discussions with a top-20 global Pharma company to explore opportunities for the sales, distribution, and marketing of the Egoo Health platform, as well as to advance a potential...

<div class="abstract">Qlife has been in discussions with a top-20 global Pharma company to explore opportunities for the sales, distribution, and marketing of the Egoo Health platform, as well as to advance a potential commercial collaboration. The parties have signed a letter of intent (LOI); however, due to the early stage of negotiations, they have agreed to keep the company's identity confidential. </div>Qlife is actively pursuing a partnership strategy and, with recent advancements in the Egoo Health product lines, expects to establish one or more partnerships during 2025. These collaborations will focus on the commercialization of specific disease areas within the Egoo Health platform. "We are pleased to see growing interest in the Egoo Health platform, particularly as we transition the company toward commercialization. We believe it is realistic for the company to establish partnerships with leading companies in specific disease fields this year. This LOI represents an important first step in executing our partnership strategy."- says Thomas Warthoe CEO of Qlife.<div>This disclosure contains information that Qlife Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on "This placeholder will be replaced with the correct date and send time"&gt;"This placeholder will be replaced with the correct date and send time"&gt;28-01-2025 09:00 CET.</div>

Qlife Holding AB: Qlife has signed a letter of intent with a top-20 global Pharma company to explore a potential commercial collaboration

Privacy preferences